We used 18 monoclonal antibodies against B19 parvovirus to identify neutralizing epitopes on the viral capsid. Of the 18 antibodies, 9 had in vitro neutralizing activity in a bone marrow (1, 2, 9) , and persistent infection in immunocompromised hosts like patients with AIDS and those receiving chemotherapy for leukemia (11).
Parvoviruses, the smallest DNA-containing animal viruses, are responsible for a wide variety of diseases in vertebrates (18) . In humans, diseases caused by B19 parvovirus include erythema infectiosum (fifth disease) in children and a polyarthralgia syndrome in adults (20) , transient aplastic crisis in persons with underlying hemolysis (15) , spontaneous abortion and hydrops fetalis in utero infection (1, 2, 9) , and persistent infection in immunocompromised hosts like patients with AIDS and those receiving chemotherapy for leukemia (11) .
The period of viremia is short in individuals with normal immune function and ends with formation of specific antibodies to the virus (16) . In persistent infection, pooled human immunoglobulin is effective therapy (6) . Despite the evident importance of antibody for viral clearance and resolution of infection, the humoral response to B19 has not been well characterized and only a single neutralizing epitope has been reported (17) . We studied the reactivities of a panel of anti-B19 neutralizing monoclonal antibodies (MAbs) by using bacterium-expressed polypeptide fragments of the B19 capsid proteins. We identified a second neutralizing epitope on the VP2 capsid protein. However, most of the MAbs appeared to recognize conformational rather than linear epitopes.
MAbs were made by a modified cell fusion method (7, 10 were cultured without virus, and as a positive control, cells were cultured with virus alone. With this assay, 9 of the 18 clones (B, D, E, F, K, P, Q, R, and S) were neutralizing at titers between 1:150 and 1:3,750. The neutralizing activities were between 65 and 108% at an antibody dilution of 1:75 (Table 1) .
To determine the epitopes recognized by neutralizing antibodies, the recombinant VP1 and VP2 capsid proteins and the 11 fusion proteins containing B19 parvovirus structural protein polypeptide fragments were prepared and immunoblotting was performed. Preparation of the recombinant VP1 and VP2 capsid proteins was described previously (8) . The expression vectors were constructed as follows. DNA. segments encoding 11 recombinant proteins were amplified from pYT103c (a nearly full-length B19 cloned DNA) with adequate primers by polymerase chain reaction. Polymerase chain reactions were performed by using a standard protocol in a total volume of 100 ,ul containing polymerase chain reaction buffer (10 mM Tris-HCl [pH 8.3] , 50 mM KCI, 1.5 mM MgCl2, 0.01% gelatin), the four deoxynucleoside triphosphates at 200 ,uM each, 2.5 U of Taq polymerase (Perkin Elmer Cetus, Norwalk, Conn.), adequate primers (21-mer), and pYT103c (a template). After purification of the amplified DNAs from an agarose gel, they were inserted into a StuI site of maltose-binding protein vector pMAL-c (Fig. 1A) , which carried a termination codon created by insertion of an XbaI linker (New England Biolabs, Inc., Beverly, Mass.) into a blunt-ended EcoRI site. Only a single neutralizing MAb, E, showed reactivity with both VP1 and VP2 capsid proteins (Fig. 2) . Since the entire sequence of VP2 is contained within VP1, MAb E recognizes a linear epitope of the VP2 capsid protein. MAb E reacted with fusion proteins of the expected sizes (53 to 54 kDa) on immunoblot, and this reactivity was restricted to the VPF6 fusion protein (Fig. 3A and B) . To determine in further detail the epitope recognized by MAb E, four short fragments of VPF6 were prepared by the same method and designated SF1, SF2, SF3, and SF4 (Table 2) . When the reactivities of these four short fragments of VPF6 were tested by immunoblot, only SF3 reacted with MAb E (Fig. 4) , indicating that the epitope recognized by MAb E was localized to 21 amino acids lying between residues 57 and 77 of VP2.
The genome of the B19 parvovirus is approximately 5.4 kb long and contains two major open reading frames (5) . The left open reading frame encodes the 71-kDa nonstructural protein (NS), and the right open reading frame encodes the two capsid proteins VP1 and VP2. The entire sequence of VP2 is contained within VP1; the two amino acid sequences are identical except for the amino-terminal 226 residues of VP1. In virions, VP1 represents only about 5% of the capsid proteins and the remainder is composed of VP2 (3, 4) . While no detailed structural data are available for B19 parvovirus, the structure of the related canine parvovirus (CPV) has been solved to the atomic level by X-ray crystallography (19) . While the structural relationship of this virus to B19 can be extrapolated only tentatively, the amino acid sequences of the capsid proteins share 41% homology and 19% identity and most major structural features appear to be conserved in B19 parvovirus (Fig. 5) . A single neutralizing epitope has been reported for B19 parvovirus and mapped to residues 328 to 344 of VP2 (17) . This region corresponds to amino acids 355 to 373 of CPV and contributes to the spike on the threefold axis of the virion. None of our neutralizing MAbs recognized this epitope, but MAb E recognized a region from residues 57 to 77 of VP2 corresponding to 71 to 91 on CPV. Both neutralizing epitopes are also present on VP1. These amino acids of CPV also fold to the spike. Two neutralizing epitopes mapping to residues Ala-300 and Asn-93 have been identified on CPV (14) . Despite their separation in the linear sequence of the capsid proteins, both of these residues also map to the spike on the threefold axis and they may correspond structurally to the neutralizing regions identified on B19 parvovirus.
Of the nine neutralizing MAbs that we studied, only one reacted with the capsid proteins and the peptide fragments on an immunoblot. These MAbs were originally screened by the radioimmunoassay, and under these conditions the conformational structure of the virion should be preserved. It is likely that the eight unreactive MAbs recognize conformational epitopes that are no longer present on the membranetransferred protein in an immunoblot.
We have reported the generation of neutralizing antiserum in animals immunized with B19 empty capsids containing both VP1 and VP2 but not VP2 alone (8) . These results are surprising given the identification of two neutralizing epitopes on VP2. It is suspected that the presence of VP1 modulates the antigenicity of the viral particle and that the antigenicity of the those epitopes is too low to be recognized 
